Vainer Noomi, Rotbain Curovic Viktor, Niemann Carsten Utoft, Slager Susan L, Rotbain Emelie Curovic
Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Hematology Group, Danish Cancer Institute, Copenhagen, Denmark.
Expert Rev Hematol. 2024 Sep;17(9):617-629. doi: 10.1080/17474086.2024.2383417. Epub 2024 Jul 26.
Comorbidities play an important role in the management of chronic lymphocytic leukemia (CLL) and may influence survival and treatment outcomes. Considering the aging general population and increasing incidence of type 2 diabetes (T2D), a comprehensive understanding of the interplay between CLL and T2D is essential for optimizing care and outcomes.
We present current knowledge on co-existing CLL and T2D including prevalence, shared etiology and risk factors and how the conditions and treatment hereof may influence the outcome of one another. A literature search was performed using PubMed with the cutoff date on 1 February 2024.
The increased mortality observed in persons with CLL who have co-existing T2D is partially ascribed to infections, prompting physicians managing individuals with both conditions to consider closer monitoring during instances of infection and individualized prophylaxis. People with CLL and T2D should be managed for CLL in accordance with the international working group on CLL criteria, and we recommend that physicians exercise particular care not to delay treatment for these individuals. Multidisciplinary approaches with involvement of several specialties may be required for optimal supportive care of co-occurring T2D and CLL.
合并症在慢性淋巴细胞白血病（CLL）的管理中起着重要作用，可能影响生存和治疗结果。鉴于总体人群老龄化以及2型糖尿病（T2D）发病率不断上升，全面了解CLL与T2D之间的相互作用对于优化护理和治疗结果至关重要。
我们介绍了关于CLL与T2D并存的现有知识，包括患病率、共同病因和危险因素，以及这些疾病及其治疗如何相互影响彼此的结果。使用PubMed进行了文献检索，截止日期为2024年2月1日。
在患有T2D的CLL患者中观察到的死亡率增加部分归因于感染，这促使同时管理这两种疾病患者的医生在感染期间考虑加强监测和个体化预防。患有CLL和T2D的患者应根据CLL国际工作组标准进行CLL管理，我们建议医生特别注意不要延误这些患者的治疗。对于同时发生的T2D和CLL的最佳支持性护理，可能需要多学科方法，涉及多个专科。
